Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma

Cancer

Volumn 101, Issue 1, 2004, Pages 77-82

  Blackwell, Kimberly ^a,c   Hurwitz, Herbert ^a   Liebérman, Grazyna ^b   Novotny, William ^b   Snyder, Stacey ^a   Dewhirst, Mark ^a   Greenberg, Charles ^a  

^a DUKE CANCER INSTITUTE   (United States)

^b GENENTECH INC   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Carcinoembryonic antigen; Colorectal carcinoma; D dimer; Metastasis

Indexed keywords

BEVACIZUMAB; CARCINOEMBRYONIC ANTIGEN; D DIMER; FLUOROURACIL; FOLINIC ACID;

ADULT; AGED; ANGIOGENESIS; ANTIGEN DETECTION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE MARKER; FEMALE; FIBRIN FORMATION; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ASSAY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 3042529038     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20336     Document Type: Article

References (46)

1. Dupuy E, Habib A, Lebret M, Yang R, Levy-Toledano S, Tobelem G. Thrombin induces angiogenesis and vascular endothelial growth factor expression in human endothelial cells: possible relevance to HIF-1α. Thromb Haemost. 2003; 1:1096-1102.
2. Pirie-Shepherd SR. Regulation of angiogenesis by the hemostatic system. Front Biosci. 2003;8:d286-d293.
3. Maragoudakis ME, Tsopanoglou NE, Andriopoulou P. Mechanism of thrombin-induced angiogenesis. Biochem Soc Trans. 2002;30:173-177.
4. Wojtukiewicz MZ, Sierko E, Klement P, Rak J. The hemostatic system and angiogenesis in malignancy. Neoplasia. 2001;3:371-384.
5. Hall H, Baechi T, Hubbell JA. Molecular properties of fibrin-based matrices for promotion of angiogenesis in vitro. Microvasc Res. 2001;62:315-326.
6. Bick RL, Baker WF. Diagnostic efficacy of the D-dimer assay in disseminated intravascular coagulation (DIC). Thromb Res. 1992;65:785-790.
7. Wilde JT, Kitchen S, Kinsey S, Greaves M, Preston FE. Plasma D-dimer levels and their relationship to serum fibrinogen/fibrin degradation products in hypercoagulable states. Br J Haematol. 1989;71:65-70.
8. Devine DV, Kinney TR, Thomas PF, Rosse WF, Greenberg CS. Fragment D-dimer levels: an objective marker of vasoocclusive crisis and other complications of sickle cell disease. Blood. 1986;68:317-319.
9. Rowbotham BJ, Carroll P, Whitaker AN, et al. Measurement of crosslinked fibrin derivatives - use in the diagnosis of venous thrombosis. Thromb Haemost. 1987;57:59-61.
10. Rowbotham BJ, Whitaker AN, Masci PP. Plasma cross-linked fibrin degradation product (XLFbDP) assays in an in vivo model of fibrinolysis. Blood Coagul Fibrinolysis. 1990;1:653-661.
11. Francis CW, Connaghan DG, Scott WL, Marder VJ. Increased plasma concentration of cross-linked fibrin polymers in acute myocardial infarction. Circulation. 1987;75:1170-1177.
12. Ferrigno D, Buccheri G, Ricca I. Prognostic significance of blood coagulation tests in lung cancer. Eur Respir J. 2001; 17:667-673.
13. Kalweit GA, Feindt P, Micek M, Gams E, Hellstern P. Markers of activated hemostasis and fibrinolysis in patients with pulmonary malignancies: comparison of plasma levels in central venous and pulmonary venous blood. Thromb Res. 2000;97:105-111.
14. Pavey SJ, Hawson GA, Marsh NA. Impact of the fibrinolytic enzyme system on prognosis and survival associated with non-small cell lung carcinoma. Blood Coagul Fibrinolysis. 2001;12:51-58.
15. Roselli M, Mineo TC, Basili S, et al. Vascular endothelial growth factor (VEGF-A) plasma levels in non-small cell lung cancer: relationship with coagulation and platelet activation markers. Thromb Haemost. 2003;89:177-184.
16. Seitz R, Rappe N, Kraus M, et al. Activation of coagulation and fibrinolysis in patients with lung cancer: relation to tumour stage and prognosis. Blood Coagul Fibrinolysis. 1993;4:249-254.
17. Wajima T. Fibrinolytic profiles in patients with small cell carcinoma of the lung. Semin Thromb Hemost. 1991;17:280-285.
18. Wojtukiewicz MZ, Zacharski LR, Memoli VA, et al. Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung. Cancer. 1990;65:481-485.
19. Kohli M, Fink LM, Spencer HJ, Zent CS. Advanced prostate cancer activates coagulation: a controlled study of activation markers of coagulation in ambulatory patients with localized and advanced prostate cancer. Blood Coagul Fibrinolysis. 2002;13:1-5.
20. Nakashima J, Tachibana M, Ueno M, Baba S, Tazaki H. Tumor necrosis factor and coagulopathy in patients with prostate cancer. Cancer Res. 1995;55:4881-4885.
21. Adamson AS, Francis JL, Witherow RO, Snell ME. Coagulopathy in the prostate cancer patient: prevalence and clinical relevance. Ann R Coll Surg Engl. 1993;75:100-104.
22. Wojtukiewicz MZ, Zacharski LR, Memoli VA, et al. Fibrin formation on vessel walls in hyperplastic and malignant prostate tissue. Cancer. 1991;67:1377-1383.
23. Gadducci A, Baicchi U, Marrai R, et al. Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with operable cervical cancer: influence of surgical-pathological stage, tumor size, histologic type, and lymph node status. Gynecol Oncol. 1993;49:354-358.
24. Gadducci A, Baicchi U, Del Bravo B, et al. Evaluation of some hemostatic parameters in patients with cervical carcinoma. Eur J Gynaecol Oncol. 1990;11:215-218.
25. Oya M, Akiyama Y, Okuyama T, Ishikawa H. High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer. Jpn J Clin Oncol. 2001;31:388-394.
26. Oya M, Akiyama Y, Yanagida T, Akao S, Ishikawa H. Plasma D-dimer level in patients with colorectal cancer: its role as a tumor marker. Surg Today. 1998;28:373-378.
27. Edwards CM, Warren J, Armstrong L, Donnelly PK. D-dimer: a useful marker of disease stage in surgery for colorectal cancer. Br J Surg. 1993;80:1404-1405.
28. Montemurro P, Conese M, Altomare DF, Memeo V, Colucci M, Semeraro N. Blood and tissue fibrinolytic profiles in patients with colorectal carcinoma. Int J Clin Lab Res. 1995;25:195-200.
29. Salgado R, Benoy I, Weytjens R, et al. Arterio-venous gradients of IL-6, plasma and serum VEGF and D-dimers in human cancer. Br J Cancer. 2002;87:1437-1444.
30. Gadducci A, Baicchi U, Marrai R, Ferdeghini M, Bianchi R, Facchini V. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses. Gynecol Oncol. 1996;60:197-202.
31. Gadducci A, Marrai R, Baicchi U, et al. The measurement of plasma D-dimer (DD) levels in the follow-up of patients with ovarian cancer. Anticancer Res. 1995;15:2683-2686.
32. Rose PG, Terrien JM, Baker S. Plasma D-dimer and peritoneal CA-125 levels as predictors of disease status in ovarian carcinoma. J Surg Oncol. 1994;56:168-171.
33. Rella C, Coviello M, De Frenza N, et al. Plasma D-dimer measurement as a marker of gynecologic tumors: comparison with Ca 125. Tumori. 1993;79:347-351.
34. Mirshahi SS, Pujade-Lauraine E, Soria C, et al. D-dimer and CA 125 levels in patients with ovarian cancer during antineoplastic therapy. Prognostic significance for the success of anti-cancer treatment. Cancer. 1992;69:2289-2292.
35. Mitter CG, Zielinski CC. Plasma levels of D-dimer: a crosslinked fibrin-degradation product in female breast cancer. J Cancer Res Clin Oncol. 1991;117:259-262.
36. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60-65.
37. Maragoudakis ME, Tsopanoglou NE, Andriopoulou P. Mechanism of thrombin-induced angiogenesis. Biochem Soc Trans. 2002;30:173-177.
38. Chiarug V, Ruggiero M, Magnelli L. Angiogenesis and the unique nature of tumor matrix. Mol Biotechnol. 2002;21:85-90.
39. Wojtukiewicz MZ, Sierko E, Klement P, Rak J. The hemostatic system and angiogenesis in malignancy. Neoplasia. 2001;3:371-384.
40. Simpson-Haidaris PJ, Rybarczyk B. Tumors and fibrinogen. The role of fibrinogen as an extracellular matrix protein. Ann N Y Acad Sci. 2001;936:406-425.
41. Wojtukiewicz MZ, Zimnoch L, Jaromin J, Kloczko J, Bielawiec M, Matuszewska EA. Immunohistochemical demonstration of fibrin II in gastric cancer tissue. Pol J Pharmacol. 1996;48:229-232.
42. Bell WR. The fibrinolytic system in neoplasia. Semin Thromb Hemost. 1996;22:459-478.
43. Dvorak HF, Harvey VS, Estrella P, Brown LF, McDonagh J, Dvorak AM. Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. Lab Invest. 1987;57:673-686.
44. Nicosia RF, Tchao R, Leighton J. Angiogenesis-dependent tumor spread in reinforced fibrin clot culture. Cancer Res. 1983;43:2159-2166.
45. Bugge TH, Kombrinck KW, Xiao Q, et al. Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice. Blood. 1997;90:4522-4531.
46. Palumbo JS, Potter JM, Kaplan LS, Talmage K, Jackson DG, Degen JL. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res. 2002; 62:6966-6972.